{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:41:35Z","timestamp":1787010095173,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Immunotherapy has become an integral part of management in patients with advanced non\u2013small cell lung cancer (NSCLC). Programmed death ligand 1 (PD-L1) expression in at least 50% of tumor cells on histologic samples has been correlated with improved efficacy of the immune checkpoint inhibitor pembrolizumab. A limited number of studies have examined the suitability of endobronchial ultrasound\u2013guided transbronchial needle aspiration (EBUS-TBNA) specimens for assessment of PD-L1 status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We sought to examine the feasibility and results of PD-L1 testing performed on EBUS-TBNA samples acquired for the diagnosis and staging of NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Patients were identified from a prospectively maintained pathology database. Baseline characteristics were tabulated. Hematoxylin and eosin slides were reviewed to categorize cellularity between &lt;100, 100 to 500, and &gt;500 viable tumor cells. Samples were tested using Dako\u2019s PD-L1 IHC 22C3 pharmDx kit, with a minimum of 100 viable tumor cells. For patients in whom additional tissue samples were available, the results of PD-L1 testing were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>PD-L1 testing was attempted on 120 EBUS-TBNA samples. The most common NSCLC subtype was adenocarcinoma (78%). Seventy-six specimens (63%) had a cellularity &gt;500 tumor cells. Among 110 of 120 (92%) patients with an adequate endobronchial ultrasound (EBUS) sample, 53 of 110 (48.2%) had high PD-L1 expression, defined as a Tumor Proportion Score \u226550%. EBUS PD-L1 results were concordant with an available histologic sample in 14 of 18 patients (78%), with no false-negative results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>PD-L1 testing was feasible in the majority of EBUS-TBNA samples acquired for the diagnosis and staging of NSCLC. Comparison of EBUS results with histologic samples revealed moderate concordance, with no false-negative results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/lbr.0000000000000623","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T06:14:18Z","timestamp":1568182458000},"page":"50-57","source":"Crossref","is-referenced-by-count":22,"title":["Programmed Death Ligand 1 Testing of Endobronchial Ultrasound\u2013guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non\u2013Small Cell Lung Cancer"],"prefix":"10.1097","volume":"27","author":[{"given":"Allister","family":"Smith","sequence":"first","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Divisions of Pathology and Molecular Genetics, Optilab-McGill University Health Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Zerbo","sequence":"additional","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Beaudoin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Respiratory Division, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ofiara","sequence":"additional","affiliation":[{"name":"Department of Medicine, Respiratory Division, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Olivier","family":"Fiset","sequence":"additional","affiliation":[{"name":"Divisions of Pathology and Molecular Genetics, Optilab-McGill University Health Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Benedetti","sequence":"additional","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne V.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre"},{"name":"Department of Medicine, Respiratory Division, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"R2-20230927","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1164\/rccm.201702-0433CI","article-title":"AJRCCM: 100-year anniversary. The shifting landscape for lung cancer: past, present, and future","volume":"195","author":"Vachani","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R4-20230927","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jtho.2018.01.002","article-title":"Progress in the management of advanced thoracic malignancies in 2017","volume":"13","author":"Ferrara","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R5-20230927","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20230927","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"R7-20230927","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R8-20230927","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-20230927","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20230927","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.chest.2018.07.017","article-title":"Comparison of programmed death ligand-1 immunohistochemical staining between endobronchial ultrasound transbronchial needle aspiration and resected lung cancer specimens","volume":"154","author":"Sakata","year":"2018","journal-title":"Chest"},{"key":"R12-20230927","doi-asserted-by":"crossref","first-page":"e211S","DOI":"10.1378\/chest.12-2355","article-title":"Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Silvestri","year":"2013","journal-title":"Chest"},{"key":"R14-20230927","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R15-20230927","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/dc.23900","article-title":"Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer","volume":"46","author":"Biswas","year":"2018","journal-title":"Diagn Cytopathol"},{"key":"R16-20230927","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/cncy.21941","article-title":"Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy","volume":"126","author":"Stoy","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"R17-20230927","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.arbres.2017.10.008","article-title":"PD-L1 expression in a non-small cell lung cancer specimen obtained by EBUS-TBNA","volume":"54","author":"Fernandez-Bussy","year":"2018","journal-title":"Arch Bronconeumol"},{"key":"R18-20230927","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jasc.2017.06.107","article-title":"PD-L1 assessment in thoracic cytology samples","volume":"6","author":"Lerner","year":"2017","journal-title":"J Am Soc Cytopathol"},{"key":"R19-20230927","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jasc.2017.06.110","article-title":"Loss of PD-L1 immunoexpression in cytolyt-fixed cell blocks","volume":"6","author":"Alex","year":"2017","journal-title":"J Am Soc Cytopathol"},{"key":"R20-20230927","first-page":"1823","article-title":"Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer","volume":"375","author":"Wang","year":"2018","journal-title":"Ann Oncol"},{"key":"R21-20230927","doi-asserted-by":"crossref","first-page":"26845","DOI":"10.18632\/oncotarget.15839","article-title":"PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"R22-20230927","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Ettinger","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"R23-20230927","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1378\/chest.15-1216","article-title":"Technical aspects of endobronchial ultrasound-guided transbronchial needle aspiration: CHEST Guideline and Expert Panel Report","volume":"149","author":"Wahidi","year":"2016","journal-title":"Chest"},{"key":"R24-20230927","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jasc.2017.06.112","article-title":"Rapid On-site Evaluation (ROSE) of endobronchial ultrasound-guided fine-needle aspiration (EBUS-TBNA) optimizes tissue for evaluation of PD-L1 expression on formalin-fixed non-small cell lung carcinoma","volume":"6","author":"Doxtader","year":"2017","journal-title":"J Am Soc Cytopathol"},{"key":"R25-20230927","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncy.21987","article-title":"Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations","volume":"126","author":"Noll","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"R26-20230927","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cncy.21937","article-title":"PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens","volume":"125","author":"Heymann","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"R27-20230927","first-page":"S815","article-title":"P2.01-048 paired comparison of PDL1 assessment on cytology and histology from malignancies in the lung","volume":"12","author":"Skov","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R28-20230927","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cncy.21973","article-title":"Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas","volume":"126","author":"Russell-Goldman","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"R29-20230927","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/PAI.0000000000000458","article-title":"Fading with time of PD-L1 immunoreactivity in non-small cells lung cancer tissues: a methodological study","volume":"26","author":"Giunchi","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R30-20230927","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1164\/rccm.201712-2539PP","article-title":"The immune landscape of non-small-cell lung cancer. Utility of cytologic and histologic samples obtained through minimally invasive pulmonary procedures","volume":"198","author":"Beattie","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"R31-20230927","doi-asserted-by":"crossref","first-page":"682","DOI":"10.21037\/tlcr.2018.06.09","article-title":"Predictive markers for anti-PD-1\/PD-L1 therapy in non-small cell lung cancer-where are we?","volume":"7","author":"Evans","year":"2018","journal-title":"Transl Lung Cancer Res"}],"container-title":["Journal of Bronchology &amp; Interventional Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/LBR.0000000000000623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T01:19:05Z","timestamp":1695777545000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/LBR.0000000000000623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/lbr.0000000000000623","relation":{},"ISSN":["1944-6586"],"issn-type":[{"value":"1944-6586","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,10]]}}}